Sun Pharma’s Taro recalls 17,100 dandruff care kits in US

NEW DELHI: Drug major Sun Pharma arm Taro Pharmaceuticals USA Inc is recalling 17,100 kits of Kamedis Bio-Herbal dandruff care kits in the US on account of being sub-potent drug.

"Taro Pharmaceuticals USA Inc is recalling the drug because of it being subpotent drug: out of specification assay values on stability for the active ingredient, zinc pyrithione," the latest Enforcement Report of health regulator USFDA has said.

The therapeutic 2-step Kamedis Bio-Herbal Dandruff Care System is used for treating itching and flaking associated with dandruff and seborrheic dermatitis.

The voluntary nationwide ongoing recall is a class III recall, US Food and Drug Administration (USFDA) said.

According to USFDA, a class III recall is initiated in "a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences".